Posted inNews and Updates
WHO Launches Clinical Trial for Obeldesivir in Ebola Fight
The WHO has launched a clinical trial for Gilead’s obeldesivir to treat the Bundibugyo Ebola virus, marking a key step in developing new viral therapies.
Posted inNews and Updates
BlueCross BlueShield Updates Coverage Policy for FibroScan
BlueCross BlueShield of Tennessee updates medical policies for FibroScan and noninvasive elastography. Learn what this means for liver disease diagnosis.
Posted inNews and Updates
FDA Finalizes New Guidance for Psychedelic Drug Research
The FDA has issued final guidance for clinical trials involving psychedelic drugs, setting new standards for safety, trial design, and patient monitoring.
Posted inNews and Updates
New Anti-PD-L1 Immunotherapy for Alzheimer’s Shows Promise
A Phase 1b clinical trial explores a new short-lived anti-PD-L1 antibody treatment for Alzheimer’s disease, targeting neuro-inflammation and plaque clearance.
Posted inNews and Updates
New Malaria Drug Shows Promise in Early Clinical Trials
A new malaria drug candidate has cleared Phase I clinical trials with positive safety results, offering fresh hope against drug-resistant parasites.
Posted inNews and Updates
FDA Clears MAX-001 Phase 2 Trial for Acute Pain Treatment
Maxona Pharmaceuticals earns FDA clearance for the Phase 2 clinical trial of MAX-001, a novel non-opioid treatment for acute pain management.
Posted inNews and Updates
Intensity Therapeutics Resumes INVINCIBLE-4 Cancer Trial
Intensity Therapeutics has resumed its INVINCIBLE-4 Phase 2 trial for triple-negative breast cancer. Discover the latest on this innovative cancer study.
Posted inNews and Updates
Clinical Trials Market Projected to Hit $176B by 2030
The clinical trials market is set to hit $176B by 2030. Discover how AI and decentralized research models are accelerating drug development worldwide.
Posted inNews and Updates
FDA Clears Clinical Trial for Novel ATR 1072 Treatment
The FDA has authorized Atrium’s IND application for ATR 1072. Learn about this new clinical trial milestone and the future of this therapeutic development.
Posted inNews and Updates
Sound Pharmaceuticals Completes SPI-1005 Clinical Trial
Sound Pharmaceuticals has wrapped up enrollment for its Phase 3 SPI-1005 trial, targeting new treatments for sensorineural hearing loss and Meniere’s disease.